Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
  • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
  • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
  • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
  • B65D65/00—Wrappers or flexible covers; Packaging materials of special type or form
  • B65D65/38—Packaging materials of special type or form
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
  • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
• • C—CHEMISTRY; METALLURGY
  • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
  • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
  • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
  • C08L67/02—Polyesters derived from dicarboxylic acids and dihydroxy compounds
  • C08L67/03—Polyesters derived from dicarboxylic acids and dihydroxy compounds the dicarboxylic acids and dihydroxy compounds having the carboxyl- and the hydroxy groups directly linked to aromatic rings
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
  • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
  • Y10T428/00—Stock material or miscellaneous articles
  • Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
  • Y10T428/1352—Polymer or resin containing [i.e., natural or synthetic]
  • Y10T428/1397—Single layer [continuous layer]

Definitions

• the present invention relates to a product which contains prostaglandin, wherein an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water is stored in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate, thereby inhibiting the decrease of the content of the prostaglandin derivative in the aqueous liquid preparation.
• Prostaglandin is a physiologically active substance, and a number of prostaglandin derivatives have been studied and developed.
• prostaglandin derivatives which are useful as therapeutic agents for glaucoma and ocular hypertension are reported in Japanese Patent No. 2721414, and JP-A Nos. H02-108 and H11-71344.
• prostaglandin derivatives are liable to be adsorbed on a container and have a property being slightly soluble in water.
• aqueous liquid preparations containing the prostaglandin derivative having such properties it is necessary to improve the matters of adsorptivity on a container and solubility in water.
• known materials of resin containers for storing an aqueous liquid preparation such as eye drops are exemplified by polyethylene, polypropylene, polyethylene terephthalate, polyvinyl chloride, acrylic resins, polystyrene, polymethylmethacrylate, nylon 6 and the like.
• JP-T No. 2002-520368 discloses that a prostaglandin product containing prostaglandin and a surfactant is more stabilized in the case in which it is stored in a polypropylene resin container than in the case in which it is stored in a polyethylene resin container. Also, WO 2002/22106 A1 discloses that prostaglandin can be stably stored in a resin container comprising polypropylene. JP-A No.
• 2002-161037 discloses an invention wherein solubility in water and adsorptivity on a resin container of a prostaglandin derivative are improved by incorporating a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60 in an aqueous liquid preparation.
• a nonionic surfactant such as polysorbate 80 or polyoxyethylene hydrogenated castor oil 60
• the resin container itself for storing an aqueous liquid preparation has not been studied.
• the present inventors elaborately made studies of materials of resin containers suited for storing an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water, and found that the decrease of the content of the prostaglandin derivative in an aqueous liquid preparation can be markedly inhibited when stored in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate.
• the present invention was accomplished.
• the invention relates to the following aspects.
• the prostaglandin derivative used in the invention is not particularly limited as long as it is a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water (hereinafter, referred to as "the present prostaglandin derivative") but can be preferably a prostaglandin F2 ⁇ derivative having a fluorine atom or fluorine atoms in the molecule disclosed in JP-A No. H11-71344 or H10-251225, more preferably, a difluoroprostaglandin F2 ⁇ derivative disclosed in JP-A No. H11-71344, and particularly preferably a difluoroprostaglandin F2 ⁇ derivative having two fluorine atoms at position 15 disclosed in JP-A No. H11-71344.
• prostaglandin derivative 16-phenoxy-15-deoxy-15, 15-difluoro-17, 18, 19, 20-tetranorprostaglandin F2 ⁇ , 16-(3-chlorophenoxy)-15-deoxy-15, 15-difluoro-17, 18, 19, 20-tetranorprostaglandin F2 ⁇ , 16-phenoxy-15-deoxy-15, 15-difluoro-13, 14-dihydro-17, 18, 19, 20-tetranorprostaglandin F2 ⁇ , or alkyl esters thereof, or salts of the same.
• alkyl ester examples include lower alkyl esters such as methyl ester, ethyl ester, propyl ester, isopropyl ester, tert-butyl ester, pentyl ester and hexyl ester.
• the "prostaglandin derivative being liable to be adsorbed on a container” referred to herein means that the content (the “content” referred to herein meaning the amount that is present as being dissolved in an aqueous solution to the amount of the present prostaglandin allowed for dissolution) of the prostaglandin derivative is drastically reduced when a prostaglandin aqueous solution is stored in a container.
• the phrase refers to the state in which the compound is adsorbed on the container in an amount of 10% or more after storing in a polyethylene container or a polypropylene container at 60°C for one week.
• the "prostaglandin derivative that is slightly soluble in water” referred to herein means one which requires 1000 ml or more water for dissolving 1 g of the prostaglandin derivative (The Pharmacopeia of Japan, thirteenth ed., Description, General principle A-51 (1996)).
• the "resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate” means a resin container made from a polymer alloy obtained by polymer-alloying polyethylene terephthalate with polyarylate.
• Examples of the process for the polymer alloying are block copolymerization, graft copolymerization, polymer blend and the like.
• the polyethylene terephthalate is a polycondensate of ethylene glycol and terephthalic acid or terephthalate diester
• the polyarylate is a polycondensate of bisphenol A and terephthalic acid, isophthalic acid or an ester thereof, or the like.
• the polyethylene terephthalate and polyarylate used in the invention can be obtained by any polycondensation method.
• the polymer alloy of polyethylene terephthalate and polyarylate used in the invention can be obtained by any process of block copolymerization, graft copolymerization or polymer blend, and can be obtained by, for example, adding an additive such as an alkali metal salt or a heat stabilizer to a mixture of the polyethylene terephthalate and the polyarylate, followed by heating.
• an additive such as an alkali metal salt or a heat stabilizer
• Examples of commercially available polymer alloy of polyethylene terephthalate and polyarylate are U-8000, U-8400H manufactured by Unitika Ltd., and the like.
• the resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate is obtained by fabrication of the polymer alloy of polyethylene terephthalate and the polyarylate. Examples of the process for the fabrication are injection blow molding.
• the shape of the container is not any how limited.
• a nonionic surfactant can be added to the aqueous liquid preparation, and thus, the nonionic surfactant inhibits the decrease of the content of the present prostaglandin derivative in the aqueous liquid preparation through improving the solubility in water of the present prostaglandin derivative.
• nonionic surfactant examples include polyoxyethylene fatty acid esters such as polysorbate 80 [polyoxyethylene sorbitan monooleate], polysorbate 60 [polyoxyethylene sorbitan monostearate], polysorbate 40 [polyoxyethylene sorbitan monopalmitate], polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan trioleate and polysorbate 65 [polyoxyethylene sorbitan tristearate]; polyoxyethylene hydrogenated castor oils such as polyoxyethylene hydrogenated castor oil 10, polyoxyethylene hydrogenated castor oil 40, polyoxyethylene hydrogenated castor oil 50 and polyoxyethylene hydrogenated castor oil 60; polyoxyethylene polyoxypropylene glycols such as polyoxyethylene (160) polyoxypropylene (30) glycol [Pluronic F68], polyoxyethylene (42) polyoxypropylene (67) glycol [Pluronic P123], polyoxyethylene (54) polyoxypropylene (39) glycol [Pluronic P85], polyoxyethylene (196) polyoxypropylene
• nonionic surfactant Preferred examples of the nonionic surfactant are polysorbate 80 [polyoxyethylene sorbitan monooleate], polyoxyethylene hydrogenated castor oil 60, polyoxyl 40 stearate and the like. These nonionic surfactants can be used alone, or in combination of two or more thereof. Particularly preferred nonionic surfactant is polysorbate 80 [polyoxyethylene sorbitan monooleate] or polyoxyethylene hydrogenated castor oil 60, which has been widely used as an additive of eye drops.
• the prostaglandin-containing product of the invention exists in the state in which the present prostaglandin is dissolved in water, while the amount (concentration) of the present prostaglandin can be selected appropriately in consideration of the application and the like of the aqueous liquid preparation.
• the amount (concentration) of the present prostaglandin derivative in the eye drops can be selected appropriately depending on the objective disease, symptoms and the like, which can be preferably 0.00005 to 0.05%.
• the nonionic surfactant is added to an eye drop, the amount of the nonionic surfactant can be also altered appropriately depending on the amount of the present prostaglandin derivative.
• the concentration of the nonionic surfactant is preferably selected to be five times or greater the concentration of the present prostaglandin derivative.
• the concentration is particularly preferably selected to be 10 times or greater.
• the prostaglandin-containing product of the invention is an eye drop
• a variety of pharmaceutically acceptable additives e.g., an anti-oxidant such as ethylenediamine tetraacetic acid or dibutyl hydroxytoluene; a tonicity agent such as sodium chloride, potassium chloride, calcium chloride, glycerol or propylene glycol; a buffer such as boric acid, borax, citric acid, disodium hydrogenphosphate or ⁇ -aminocaproic acid; a preservative such as benzalkonium chloride, chlorhexidine gluconate, benzethonium chloride, sorbic acid, potassium sorbate, ethyl parahydroxybenzoate or butyl parahydroxybenzoate, or the like can be added in addition to the aforementioned nonionic surfactant.
• the method for preparing the eye drop containing the present prostaglandin derivative can be any conventional method for preparation without need of special procedure or operation. Also, it is preferred that the pH
• the decrease of the content of the present prostaglandin derivative in the aqueous liquid preparation can be markedly inhibited in comparison with the cases in which it is stored in any one of polyethylene containers, polypropylene containers and polyethylene terephthalate containers.
• the resin container was obtained through fabrication by injection blow molding of a polymer alloy of polyethylene terephthalate and polyarylate [U-8000 (manufactured by Unitika Ltd.), with the polyethylene terephthalate of about 45%, and the polyarylate of about 55%]. Also, the resin container for comparison was obtained through fabrication by injection blow molding of polyethylene [Petrocene 175K (manufactured by Tosoh Corporation), low density polyethylene], polypropylene [J-225W (manufactured by Mitsui Chemicals, Inc.)] and polyethylene terephthalate [PIFG5H (manufactured by Kanebo Gohsen, Ltd.)], respectively.
• All of the containers are containers for eye drops having the same shape.
• (3) Test Method After subjecting each resin container obtained in the above section "(2) Manufacture of Resin Container” to a sterilization treatment, therein was charged the eye drop obtained in the above section " (1) Preparation of Eye Drops". Then, these samples were placed in an aluminum moisture-proof bag. After storage at 60°C for one week, the content of the present compound in each resin container was measured by a high performance liquid chromatographic method. The obtained results are shown in Table 1. In Example and Comparative Examples in the Table, each content value is the mean value of three cases.
• the content of the present compound was determined using as the standard (100%), the content of the present compound following storage at 5°C for one week of the eye drop obtained in the above section "(1) Preparation of Eye Drop" charged in a glass container followed by sealing.
• Table 1 Material of the container Content of the present compound (%) Example 1 PET/PAR* 1 97.0 Comparative Example 1 LDPE* 2 83.1 Comparative Example 2 PP* 3 91.0 Comparative Example 3 PET* 4 91.8 *1: U-8000 (manufactured by Unitika Ltd.) *2: Petrocene 175K (manufactured by Tosoh Corporation) *3: J-225W (manufactured by Mitsui Chemicals, Inc.) *4: PIFG5H (manufactured by Kanebo Gohsen, Ltd.) (4) Conclusion As is clear from Table 1, when the present compound was stored in a resin container formed from a polymer alloy of polyethylene terephthalate and polyarylate, excellent storage stability was achieved exhibiting higher content
• the decrease of the content of the prostaglandin derivative that is an active ingredient in an aqueous liquid preparation is inhibited, thereby enabling storage in a stable manner of an aqueous liquid preparation containing a prostaglandin derivative that is liable to be adsorbed on a container and slightly soluble in water.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Polymers & Plastics (AREA)
• General Chemical & Material Sciences (AREA)
• Ophthalmology & Optometry (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Mechanical Engineering (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (3)

Family

ID=34113821

Family Applications (1)

Country Status (5)

Cited By (5)

Families Citing this family (4)

Citations (2)

Family Cites Families (13)

• 2004
  • 2004-07-30 WO PCT/JP2004/011282 patent/WO2005011704A1/ja not_active Application Discontinuation
  • 2004-07-30 DE DE602004024427T patent/DE602004024427D1/de not_active Expired - Fee Related
  • 2004-07-30 AT AT04771296T patent/ATE450264T1/de not_active IP Right Cessation
  • 2004-07-30 US US10/566,826 patent/US20060199863A1/en not_active Abandoned
  • 2004-07-30 EP EP04771296A patent/EP1666043B1/de not_active Not-in-force
• 2013
  • 2013-02-27 US US13/778,931 patent/US20130178524A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events